Citation Impact
Citing Papers
Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management
2000
Bactericidal/permeability-increasing protein—Lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia
2001
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
2009 Standout
Pediatric sepsis and multiple organ dysfunction syndrome
2001
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
Amrinone in pediatric refractory septic shock: An open-label pharmacodynamic study
2001
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials
2001 Standout
The Acute Respiratory Distress Syndrome
2000 Standout
Drotrecogin Alfa (Activated) in Adults with Septic Shock
2012 Standout
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
2004 Standout
Concept of PIRO as a new conceptual framework to understand sepsis
2005
Role of the bactericidal/permeability-increasing protein in host defence
1998
Progressive Statistics for Studies in Sports Medicine and Exercise Science
2008 Standout
The Pharmacokinetics of Milrinone in Pediatric Patients after Cardiac Surgery
1999
Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery
2001
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
2010 Standout
Toll-like receptor signalling
2004 Standout
International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics*
2005 Standout
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
2005 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Sepsis and septic shock
2018 Standout
Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase*
2011
Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock
2004
Transcriptional Instability during Evolving Sepsis May Limit Biomarker Based Risk Stratification
2013
Hydrocortisone Therapy for Patients with Septic Shock
2008 Standout
Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients
2001
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
2013 Standout
Endotoxin antagonism: conceptual basis and therapeutic potential
2002 StandoutNobel
Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme
1999
Emerging drugs for the treatment of sepsis
2016
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*
2009
Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock*
2002
Human hemoglobin-derived peptides exhibit antimicrobial activity: a class of host defense peptides
2003
Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation
2000
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Antimicrobial peptides of multicellular organisms
2002 StandoutNature
E5531, a synthetic non‐toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide
1999
The Epidemiology of Sepsis in the United States from 1979 through 2000
2003 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Inferences, questions and possibilities in Toll-like receptor signalling
2004 StandoutNatureNobel
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
Antifouling Coatings: Recent Developments in the Design of Surfaces That Prevent Fouling by Proteins, Bacteria, and Marine Organisms
2010 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
A Lipopolysaccharide‐Deficient Mutant ofNeisseria meningitidisElicits Attenuated Cytokine Release by Human Macrophages and Signals via Toll‐like Receptor (TLR) 2 but Not via TLR4/MD2
2001
The immunopathogenesis of sepsis
2002 StandoutNature
The Epidemiology of Severe Sepsis in Children in the United States
2003
Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide
1999
Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update
2004
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
Toll-Like Receptors
2003 Standout
Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock
2003
Assessment of Clinical Criteria for Sepsis
2016 Standout
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
2016 Standout
Hemodynamic Support in Fluid-refractory Pediatric Septic Shock
1998
Bacterial lipopolysaccharides and innate immunity.
2001
Preventing Complications of Central Venous Catheterization
2003 Standout
CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
2010 Standout
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
2020 Standout
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
Part 9: Post–Cardiac Arrest Care
2010 Standout
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
2004 Standout
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
2001 Standout
Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management
2000
A Randomized Trial of Protocol-Based Care for Early Septic Shock
2014 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Lipopolysaccharide Endotoxins
2002 Standout
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
2001 Standout
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
2009 Standout
Parâmetros de prática clínica para suporte hemodinâmico a pacientes pediátricos e neonatais em choque séptico
2002
Phylogenetic Perspectives in Innate Immunity
1999 StandoutScienceNobel
Part 14: Pediatric Advanced Life Support
2010 Standout
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
2010 Standout
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
IL-1 Receptor-Associated Kinase Modulates Host Responsiveness to Endotoxin
2000
Peptide Antibiotics
1999
Works of Phil Barton being referenced
Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis
1997
Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock
1998
Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial
2000
Hemodynamic Effects of IV Milrinone Lactate in Pediatric Patients With Septic Shock
1996
PHARMACOKINETICS AND PHARMACODYNAMICS OF MILRINONE LACTATE IN PEDIATRIC PATIENTS WITH SEPTIC SHOCK. † 288
1996